New research suggests that with high levels of vaccination and immunity from previous infections, COVID antivirals are no longer working as well.
Articles on Paxlovid
Displaying all articles
Now there’s more speculation about US President Joe Biden’s health. But a COVID diagnosis in 2024 is nothing like one back in 2020, even for someone of his age.
Two antiviral drugs are available in Australia, but one is prescribed more routinely. Here’s what you need to know as we navigate the eighth COVID wave.
How are people with long COVID faring two years after their initial infection? Many have recovered. Some still struggle with symptoms – this is more likely for those who were initially hospitalised.
People in disadvantaged communities are less likely to access COVID antivirals. That needs to change.
While there are still far more questions than answers about long COVID-19, researchers are beginning to get a clearer picture of the health and economic consequences of the condition.
Analysis of Victoria’s winter COVID wave found Paxlovid and Lagevrio reduced the risk of hospitalisation and death. The results were better for Paxlovid, but not everyone can take it.
Rapid tests can be an incredibly useful tool for early detection of COVID-19. Unfortunately, they sometimes leave people with more questions than answers.
After taking Paxlovid for COVID and appearing to recover, some people – including US President Joe Biden – continue to test positive. What’s going on?
We hear a lot about drug-resistant bacteria. The same thing can happen with viruses.
According to a letter from Biden’s doctor, the president has a runny nose, mild fatigue and a slight cough. The letter also noted that Biden began taking an antiviral drug the morning he tested positive.
Here’s who is eligible, the benefits and side effects to consider.
The effects of COVID and a new treatment for it are leaving a bad taste in the mouth for many. How do we detect what’s salty, sweet, bitter, sour or umami?
An infectious disease doctor discusses the use, benefits and availability of a drug to prevent severe COVID-19.
New ethical issues are emerging during COVID-19 as doctors struggle with their obligations to ‘do no harm’ and respect patient autonomy.
Just as access to vaccines was vastly more difficult for low-income countries, the same is now true for the virus’ treatments: at potentially great cost to the world.
Both companies say their drugs will work against the Omicron variant, though this is based on preliminary, lab-based research.
Top contributors
-
Assistant Professor of Infectious Diseases, University of Virginia
-
Professor of Pharmaceutical Chemistry, Macquarie University
-
Associate Professor and Chief Health Officer - COVID and Health Emergencies, Burnet Institute
-
Post doctoral researcher and medical epidemiologist, The Peter Doherty Institute for Infection and Immunity
-
NHMRC Leadership Fellow UQ Centre for Clinical Research, The University of Queensland
-
Assistant Professor of Medicine, UMass Chan Medical School
-
Associate Lecturer, Sydney Pharmacy School, University of Sydney
-
Director, WHO Collaborating Centre for Viral Hepatitis, The Peter Doherty Institute for Infection and Immunity
-
Adjunct Clinical Professor, Monash University
-
Director and CEO, Burnet Institute
-
PhD candidate, La Trobe University and Unit Head, Nossal Institute for Global Health, The University of Melbourne
-
Senior Research Fellow, The Perron Institute for Neurological and Translational Science, and Research Fellow, Faculty of Health Sciences, Curtin University
-
Professor of Health Metric Sciences, University of Washington
-
Professor of Cancer Virology, University of Leeds
-
Monash University